^
Association details:
| Biomarker: | EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Primary Resistance to Combination Therapy with First- and Third-Generation EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in Trans-C797S Mutations with Co-Occurring CTNNB1 Alteration
Published date:
07/09/2020
Excerpt:
...we report a patient diagnosed with lung adenocarcinoma harboring EGFR 19Del/T790M/in trans-C797S mutations with co-occurring CTNNB1 alteration showing a negative response to combination therapy with first- and third-generation TKIs….Then he received systematic therapy with osimertinib and bevacizumab, as well as stereotactic body radiation therapy (SBRT) for the single lesion in mesocephalon. Response efficacy of the systematic therapy was evaluated as PR. The duration time from that regimen was 23 months. On December 23, 2019, the patient received repeated chest CT because of the aggravating chest distress, which revealed the enlarged primary mass in the upper lobe of his left lung, as well as the significantly increased pleural infusion.
DOI:
10.2147/OTT.S262594
